Publications by authors named "T Dahl"
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare immune responses to a COVID-19 booster vaccination between older adults and younger individuals, focusing on humoral and cellular immunity.
- Researchers found that older adults (average age 86) initially had lower immune responses after earlier vaccinations compared to younger adults (average age 39), but both groups improved their antibody levels after the booster.
- While young adults showed increased cellular immune responses after the booster, older adults did not, and their plasma showed higher levels of certain T cell activation and exhaustion markers, indicating potential immune dysfunction in the elderly.
The COVID-19 pandemic posed a challenge for people living with HIV (PLWH), particularly immune non-responders (INR) with compromised CD4 T-cell reconstitution following antiretroviral therapy (CD4 count <350 cells per mm). Their diminished vaccine responses raised concerns about their vulnerability to SARS-CoV-2 breakthrough infections (BTI). Our in-depth study here revealed chronic inflammation in PLWH and a limited anti-Spike IgG response after vaccination in INR.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied the effects of a drug called tocilizumab on heart injury in patients who had serious heart attacks.
- They found that tocilizumab didn't really change the levels of certain chemicals (CXC chemokines) that are linked to heart damage.
- However, they discovered that a different treatment called heparin affected the levels of these chemicals, showing how different medications can impact heart health differently.
Specialized pro-resolving mediators (SPMs) are key effectors of resolution of inflammation. This is highly relevant for cardiac and vessel remodeling, where the net inflammatory response contributes to determine disease outcome. Herein, we used a mice model of angiotensin (Ang)-II-induced hypertension to study the effect of the SPM Resolvin D2 (RvD2), on hypertension and cardiac remodeling.
View Article and Find Full Text PDF